Sign in: Staff/Students
The University’s Institute of Integrative Biology is collaborating with global medical technology company, Anika Therapeutics, Inc. to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis.
The purpose of this three-year research collaboration is to develop a novel MSC therapy for the treatment of OA, and if successful, is expected to yield a lead candidate that will move toward clinical development within a year of the collaboration’s completion.
Osteoarthritis is the most common chronic condition of the joints, affecting over 230 million people globally. OA can affect any joint, but it occurs most often in knees, hips, lower back, neck, small joints of the fingers, and the bases of the thumb and big toe. In normal joints, cartilage covers the end of each bone and acts as a cushion between the bones. However, osteoarthritis causes this cartilage to break down, causing pain, swelling and problems moving the joint.
Professor Anthony Hollander, Chair of Stem Cell Biology at the University, said: “Cellular therapy is already being used in some countries for osteoarthritis with some evidence that it transiently reduces pain. Our new approach to cellular therapy may provide a durable treatment for osteoarthritis.” He added: “This collaboration with Anika will allow us to accelerate any discoveries through to clinical and commercial development.”
“We are very excited to partner with the University of Liverpool and Professor Hollander to continue his research into an innovative treatment for osteoarthritis patients,” said Dr Charles H. Sherwood, Chief Executive Officer, Anika Therapeutics. “This research will consist of a novel product design and pre-clinical testing, that has the potential to produce an advanced therapy to treat the joint damage and pain caused by this debilitating condition.”
You must be logged in to post a comment.
All recent news
Winter break: How to travel safety
Liverpool academics named in global list of influential researchers
Liverpool invests in immunology cancer research
Insider Imprint student journal launches new podcast series
Event today: Brexit Information for EU Students
World-leading experimental cancer researcher Professor Christian Ottensmeier has joined Liverpool to lead a major new programme of cutting-edge #immunology #cancer research in collaboration with local #NHS partners.
Full story ➡️ https://bit.ly/2V1tpga
We are delighted to invite you to join us on Friday for '@GeorgeHarrison: Transcending the Beatles' with @bbcmerseyside legend Roger Philips, @LivUni lecturer Dr Mike Jones & award-winning film producer & widow of George #OliviaHarrison.
27 Nov | 1pm GMT: https://bit.ly/2KExIw5
We’re leading a @UKRI_News funded project with @UnileverUKI, @_brightgreen & @UoMNews that aims to provide the necessary technological advancements to make plastic products more sustainable and environmentally friendly https://bit.ly/3615q7d